[go: up one dir, main page]

MA51675B1 - Compositions pharmaceutiques pour le traitement de la douleur postopératoire - Google Patents

Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Info

Publication number
MA51675B1
MA51675B1 MA51675A MA51675A MA51675B1 MA 51675 B1 MA51675 B1 MA 51675B1 MA 51675 A MA51675 A MA 51675A MA 51675 A MA51675 A MA 51675A MA 51675 B1 MA51675 B1 MA 51675B1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
treatment
postoperative pain
amide
hyaluronic acid
Prior art date
Application number
MA51675A
Other languages
English (en)
Other versions
MA51675A (fr
Inventor
Andrea Pastorello
Fabio Bettella
Devis Galesso
Original Assignee
Fidia Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Farmaceutici S.P.A. filed Critical Fidia Farmaceutici S.P.A.
Publication of MA51675A publication Critical patent/MA51675A/fr
Publication of MA51675B1 publication Critical patent/MA51675B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques sous forme de gel comprenant une matrice hydrophile constituée d'un dérivé d'acide hyaluronique contenant un anesthésique local amide sous forme de base.
MA51675A 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire MA51675B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT201800001890A IT201800001890A1 (it) 2018-01-25 2018-01-25 Composizioni farmaceutiche per il trattamento del dolore postoperatorio
EP19705572.6A EP3743043B1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire
PCT/IB2019/050552 WO2019145863A1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Publications (2)

Publication Number Publication Date
MA51675A MA51675A (fr) 2021-04-28
MA51675B1 true MA51675B1 (fr) 2024-09-30

Family

ID=62089870

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51675A MA51675B1 (fr) 2018-01-25 2019-01-23 Compositions pharmaceutiques pour le traitement de la douleur postopératoire

Country Status (17)

Country Link
US (1) US11357858B2 (fr)
EP (1) EP3743043B1 (fr)
KR (1) KR102819336B1 (fr)
CN (1) CN111629713B (fr)
AU (1) AU2019212448B2 (fr)
CA (1) CA3086650A1 (fr)
DK (1) DK3743043T3 (fr)
EA (1) EA202091613A1 (fr)
ES (1) ES2987059T3 (fr)
FI (1) FI3743043T3 (fr)
IT (1) IT201800001890A1 (fr)
LT (1) LT3743043T (fr)
MA (1) MA51675B1 (fr)
PL (1) PL3743043T3 (fr)
PT (1) PT3743043T (fr)
SA (1) SA520412416B1 (fr)
WO (1) WO2019145863A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518860A (ja) * 2020-08-10 2024-05-08 ジロパ・インコーポレイテッド 局所送達用組成物及び方法
EP4221687A4 (fr) * 2020-09-29 2024-10-02 Ziropa, Inc. Compositions et procédés de soulagement de la douleur et d'insensibilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219587B (it) * 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
DE69627365T2 (de) * 1995-09-29 2004-02-12 Lam Pharmaceutical Corp. Verabreichungssystem mit verzoegerter freisetzung sowie langwirkende narkotische analgetika und antagonisten
IT1287967B1 (it) * 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
ITPD980169A1 (it) * 1998-07-06 2000-01-06 Fidia Advanced Biopolymers Srl Ammidi dell'acido ialuronico e dei suoi derivati e processo per la loro preparazione.
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8450475B2 (en) * 2008-08-04 2013-05-28 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
IT1395392B1 (it) * 2009-08-27 2012-09-14 Fidia Farmaceutici Geli viscoelastici come nuovi filler
IT1401498B1 (it) * 2010-07-30 2013-07-26 Mero Srl Idrogelo a base di acido ialuronico e suo uso in ortopedia
EP2484387A1 (fr) * 2011-02-03 2012-08-08 Q-Med AB Composition d'acide hyaluronique
US10272181B2 (en) * 2013-09-27 2019-04-30 Anteis S.A. Method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine and an alkaline agent, sterilized with heat

Also Published As

Publication number Publication date
FI3743043T3 (fi) 2024-10-25
AU2019212448B2 (en) 2024-08-15
CN111629713A (zh) 2020-09-04
DK3743043T3 (da) 2024-09-02
CN111629713B (zh) 2024-03-19
PT3743043T (pt) 2024-09-19
ES2987059T3 (es) 2024-11-13
SA520412416B1 (ar) 2023-02-12
EA202091613A1 (ru) 2020-10-15
PL3743043T3 (pl) 2024-11-25
KR102819336B1 (ko) 2025-06-11
KR20200113239A (ko) 2020-10-06
IT201800001890A1 (it) 2019-07-25
AU2019212448A1 (en) 2020-07-09
US11357858B2 (en) 2022-06-14
MA51675A (fr) 2021-04-28
LT3743043T (lt) 2024-10-25
WO2019145863A1 (fr) 2019-08-01
EP3743043A1 (fr) 2020-12-02
CA3086650A1 (fr) 2019-08-01
US20200360519A1 (en) 2020-11-19
EP3743043B1 (fr) 2024-07-24

Similar Documents

Publication Publication Date Title
HRP20250148T1 (hr) Specifični triptamini za uporabu u liječenju poremećaja raspoloženja
MA35513B1 (fr) Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine
MA56137B1 (fr) Sels de dihydrochlorure de valbénazine et leurs polymorphes
MA29169B1 (fr) Formulations intraveineuses d'inhibiteurs de la pde-5
EP2548552A3 (fr) Ensemble de titration pour 1-amino-alkylcyclohexanes
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA38688A1 (fr) Composition solide pour administration orale contenant de l'acide ibandronique ou un sel pharmaceutiquement acceptable de celui-ci et de la vitamine d
MA51675B1 (fr) Compositions pharmaceutiques pour le traitement de la douleur postopératoire
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
CR20230177A (es) Compuestos y composiciones como moduladores de señalización tlr
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
PH12021552358A1 (en) Compounds and compositions as modulators of tlr signaling
EP4410295A3 (fr) Utilisation de vibegron pour traiter une vessie hyperactive
EA201070315A1 (ru) Жидкая лекарственная форма конъюгата
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3960858A4 (fr) Petit médicament à base d'arn pour la prévention et le traitement de maladies liées à une l'inflammation et leur combinaison
WO2018234871A3 (fr) Compositions pour administration de médicaments et leurs procédés d'utilisation
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA50991B1 (fr) Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il
MA46778B1 (fr) Composition intranasale comprenant de la bétahistine
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
MA53372B1 (fr) Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine
EP3806865A4 (fr) Tétracycline modifiée pour le traitement des troubles de l'usage de l'alcool, de la douleur et d'autres troubles impliquant des processus inflammatoires potentiels
RU2014153924A (ru) Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов
EP3632447A4 (fr) Composition pharmaceutique pour la prévention ou le traitement d'une maladie osseuse